Generic Acanya Availability
ACANYA (benzoyl peroxide; clindamycin phosphate - gel;topical)
Manufacturer: DOW PHARM
Approval date: October 23, 2008
Strength(s): 2.5%;1.2% [RLD]
Has a generic version of Acanya been approved?
No. There is currently no therapeutically equivalent version of Acanya available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Acanya. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Compositions of clindamycin and benzoyl peroxide for acne treatment
Issued: March 31, 1998
Inventor(s): Baroody; Lloyd J. & Dow; Gordon J. & Dow; Debra A. & Lathrop; Robert
Assignee(s): Baroody; Lloyd J. Dow; Gordon J.
Compositions suitable for the treatment of acne by topical application comprise clindamycin and benzoyl peroxide. Kits for preparing the compositions include a solution of clindamycin in a first container and a gel suspension of benzoyl peroxide in a second container. Each component is stored at a pH which promotes stability, and the combination of the two components provides a final composition having a pH which promotes stability and enhances viscosity.Patent expiration dates:
- March 31, 2015✓✓
- March 31, 2015
Topical pharmaceutical formulations containing a low concentration of benzoyl peroxide in suspension in water and a water-miscible organic solvent
Issued: October 16, 2012
Inventor(s): Chang; Yunik & Dow; Gordon J.
Assignee(s): Dow Pharmaceutical Sciences, Inc.
An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.Patent expiration dates:
- August 5, 2029✓✓
- August 5, 2029
- Acanya Consumer Information (Drugs.com)
- Acanya gel Consumer Information (Wolters Kluwer)
- Acanya Consumer Information (Cerner Multum)
- Clindamycin/benzoyl peroxide gel Consumer Information (Wolters Kluwer)
- Benzoyl peroxide and clindamycin topical Consumer Information (Cerner Multum)
- Clindoxyl Advanced Consumer Information (Micromedex)
- Benzoyl peroxide and clindamycin Topical application Advanced Consumer Information (Micromedex)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|